Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis

被引：40
|
作者：
Cottrell, Mackenzie L. [1 ]
Prince, Heather M. A. [2 ]
Schauer, Amanda P. [1 ]
Sykes, Craig [1 ]
Maffuid, Kaitlyn [1 ]
Poliseno, Amanda [1 ]
Chun, Tae-Wook [3 ]
Huiting, Erin [3 ]
Stanczyk, Frank Z. [4 ]
Peery, Anne F. [5 ]
Dellon, Evan S. [5 ]
Adams, Jessica L. [6 ,7 ]
Gay, Cindy [2 ]
Kashuba, Angela D. M. [1 ,2 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Div Infect Dis, Sch Med, Chapel Hill, NC 27515 USA
[3] NIAID, HIV Immunovirol Unit, 9000 Rockville Pike, Bethesda, MD 20892 USA
[4] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[5] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC 27515 USA
[6] Univ Sci, Philadelphia Coll Pharm, Philadelphia, PA USA
[7] Cooper Univ Hosp, Early Intervent Program, Camden, NJ USA
来源：
CLINICAL INFECTIOUS DISEASES | 2019年 / 69卷 / 12期
基金：
美国国家卫生研究院;
关键词：
transgender; preexposure prophylaxis; lower gastrointestinal tract; HIV; feminizing hormone therapy; HIV; WOMEN; NUCLEOTIDE;
D O I：
10.1093/cid/ciz290
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (rho = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.
引用
收藏
页码：2201 / 2204
页数：4
相关论文
共 50 条
  • [21] Educating the Primary Care Clinician on Preexposure Prophylaxis for Human Immunodeficiency Virus A Teachable Moment
    Lu, Paul Matthew
    Shearer, Lee S.
    Edelman, E. Jennifer
    JAMA INTERNAL MEDICINE, 2016, 176 (07) : 890 - 891
  • [22] US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats
    Calabrese, Sarah K.
    Krakower, Douglas S.
    Willie, Tiara C.
    Kershaw, Trace S.
    Mayer, Kenneth H.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (05) : 884 - 889
  • [23] Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis (PrEP) Clinical Trials
    Garcia-Cremades, Maria
    Vucicevic, Katarina
    Hendrix, Craig W.
    Jayachandran, Priya
    Jarlsberg, Leah
    Grant, Robert
    Celum, Connie L.
    Martin, Michael
    Baeten, Jared M.
    Marrazzo, Jeanne
    Anderson, Peter
    Choopanya, Kachit
    Vanichseni, Suphak
    Glidden, David, V
    Savic, Radojka M.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (11) : 1873 - 1882
  • [24] Role of Preexposure Prophylaxis in the Reproductive Health of Women at Risk for Human Immunodeficiency Virus Infection
    Pollock, Lealah
    Levison, Judy
    OBSTETRICS AND GYNECOLOGY, 2018, 132 (03): : 687 - 691
  • [25] Is the United States Ready for Event-Driven Human Immunodeficiency Virus Preexposure Prophylaxis?
    Cohen, Stephanie E.
    Kelley, Colleen F.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (02) : 256 - 258
  • [26] Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring
    Koss, Catherine A.
    Liu, Albert Y.
    Castillo-Mancilla, Jose
    Bacchetti, Peter
    McHugh, Cricket
    Kuncze, Karen
    Morrow, Mary
    Louie, Alexander
    Seifert, Sharon
    Okochi, Hideaki
    MaWhinney, Samantha
    Gandhi, Monica
    Anderson, Peter L.
    AIDS, 2018, 32 (15) : 2189 - 2194
  • [27] Emergency Department-Based Human Immunodeficiency Virus Preexposure Prophylaxis Referral Program-Using Emergency Departments as a Portal for Preexposure Prophylaxis Services
    Zhao, Zezhou
    Jones, Joyce
    Arrington-Sanders, Renata
    Gladfelter, Gaby
    McDonald, Steven
    Reed, Christopher
    Myer, Deanna
    Schlenker, Noah
    Fulton, Glenn
    Jones, Tiana
    Saheed, Mustapha
    Rothman, Richard
    Hsieh, Yu-Hsiang
    SEXUALLY TRANSMITTED DISEASES, 2021, 48 (08) : E102 - E104
  • [28] Safe conception for human immunodeficiency virus-discordant couples: the preexposure prophylaxis for conception alternative
    De Carli, Gabriella
    Palummieri, Antonio
    Liuzzi, Giuseppina
    Puro, Vincenzo
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (01) : 90 - 90
  • [29] Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide
    Blackwell, Christopher W.
    Castillo, Humberto Lopez
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (06): : 673 - 676
  • [30] Mitochondrial Disorders After 12 Months of Human Immunodeficiency Virus Type 1 Preexposure Prophylaxis Based on Tenofovir Disoproxil Fumarate Plus Emtricitabine in Healthy Adults
    Munoz-Muela, Esperanza
    Mejias-Trueba, Marta
    Serna-Gallego, Ana
    Saborido-Alconchel, Abraham
    Fernandez-Perez, Susana
    Herrero, Marta
    Sotomayor, Cesar
    Gutierrez-Valencia, Alicia
    Trujillo-Rodriguez, Maria
    Lopez-Cortes, Luis F.
    JOURNAL OF INFECTIOUS DISEASES, 2025,
12345